Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease
Bruce E. Sands*,Simmy Bank‡,Charles A. Sninsky§,Malcolm Robinson∥,Seymour Katz¶,John W. Singleton#,Philip B. Miner,Michael A. Safdi**,Susan Galandiuk‡‡,Stephen B. Hanauer§§,Gary W. Varilek∥∥,Alan L. Buchman¶¶,Vance D. Rodgers##,Bruce Salzberg***,Bin Cai‡‡,John Loewy‡‡‡,Michael F. DeBruin‡‡‡,Holly Rogge‡‡‡,Mark Shapiro‡‡‡,Ullrich S. Schwertschlag‡‡‡,Bruce E. Sands,Simmy Bank,Charles A. Sninsky,Malcolm Robinson,Seymour Katz,John W. Singleton,Michael A. Safdi,Susan Galandiuk,Stephen B. Hanauer,Gary W. Varilek,Alan L. Buchman,Vance D. Rodgers,Bruce Salzberg,Bin Cai,John Loewy,Michael F. DeBruin,Holly Rogge,Mark Shapiro,Ullrich S. Schwertschlag
DOI: https://doi.org/10.1016/s0016-5085(99)70550-0
IF: 29.4
1999-07-01
Gastroenterology
Abstract:BACKGROUND & AIMS: <AbstractText Label="BACKGROUND &amp; AIMS" NlmCategory="OBJECTIVE">Recombinant human interleukin 11 (rhIL-11) is a cytokine with thrombocytopoietic activity and anti-inflammatory and mucosal protective effects. The objectives of this study were to investigate the safety and tolerability of rhIL-11 in patients with Crohn's disease and to explore the effects of dose and schedule on platelet count and Crohn's disease activity.</AbstractText>METHODS: <AbstractText Label="METHODS" NlmCategory="METHODS">A multicenter, double-masked, placebo-controlled, dose-escalation study of 76 patients with active Crohn's disease was performed. Patients were randomized to receive subcutaneous placebo or rhIL-11 at doses of 5, 16, or 40 microgram. kg-1. wk-1 given 2 or 5 times weekly for 3 weeks. Clinical and laboratory safety data were recorded, and disease activity was measured at each visit.</AbstractText>RESULTS: <AbstractText Label="RESULTS" NlmCategory="RESULTS">Subcutaneous injection of rhIL-11 generally was well tolerated. Significantly greater increases in platelet counts were found among patients receiving rhIL-11 40 microgram. kg-1. wk-1 as 2 or 5 weekly doses and 16 microgram. kg-1. week-1 as 5 weekly doses compared with patients receiving placebo (P &lt; 0.05). Patients receiving 16 microgram. kg-1. wk-1 had the highest clinical response rates, with a response seen in 42% of patients (5/12) receiving 5 weekly doses and 33% of patients (4/12) receiving 2 weekly doses, compared with 7% of patients (1/15) receiving placebo.</AbstractText>CONCLUSIONS: <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Short-term treatment with rhIL-11 is well tolerated in patients with active Crohn's disease. The thrombocytopoietic effect of rhIL-11 seems to be both dose and schedule dependent and may be minimized with retained clinical benefit in Crohn's disease at 16 microgram. kg-1. wk-1 given in 2 equal doses.</AbstractText>
gastroenterology & hepatology